Figure 9. K‐M analysis of recurrence using a Mito‐Signature in a larger group of ER(+) breast cancer patients, that were divided into sub‐groups by lymph node status, who were treated with hormonal therapy. These patients were not sub‐divided into luminal A/B subgroups. Left, LN‐positive (N = 235 patients). Right, LN‐negative (N = 531 patients). Note that LN‐positive patients with high‐expression levels of the Mito‐Signature showed a near 4‐fold increase in recurrence, while being treated with hormonal therapy (p = 2.9 e‐10). Similar results were observed in LN‐negative patients, with a near 3‐fold increase in recurrence (p = 1.7e‐07). RFS, reccurence‐free survival.